Teva Pharmaceutical Industries (TEVA) Stock
Major global manufacturer of generic and specialty medicines. Here's the price, business snapshot, and what's worth knowing about Teva Pharmaceutical Industries in October 2026.
Teva Pharmaceutical Industries Ltd (TEVA) is a global pharmaceutical company best known for its large generics business and select specialty medicines. With a market capitalisation near $22 billion, Teva supplies a broad range of off‑patent medicines alongside branded treatments in areas such as central nervous system disorders. The company has undergone significant restructuring in recent years to cut costs, manage debt and refocus R&D. Key investor considerations include pricing pressure in generics, patent cliffs for older products, ongoing litigation and the balance sheet after past acquisitions. At the same time, scale in manufacturing, a diversified product mix and potential upside from speciality drugs or successful pipeline assets can support recovery. Investors should weigh Teva’s income statement trends, cash generation, debt reduction progress and the regulatory environment. This is general information for educational purposes only and not personalised investment advice; stock prices can fall as well as rise.
Why It’s Moving
Teva Bolsters Neuroscience Pipeline with BXCL501 Acquisition as Management Raises Guidance
- Teva acquired worldwide rights to BXCL501, a potential at-home treatment for agitation currently under FDA review, significantly expanding its innovative neuroscience pipeline.
- Management raised full-year guidance for all three brands, indicating improved outlooks across key product lines.
- The stock is benefiting from broader sector tailwinds, as healthcare peers like Thermo Fisher and Medtronic also exceeded growth expectations, reinforcing positive sentiment in the health care space.
Teva Bolsters Neuroscience Pipeline with BXCL501 Acquisition as Management Raises Guidance
- Teva acquired worldwide rights to BXCL501, a potential at-home treatment for agitation currently under FDA review, significantly expanding its innovative neuroscience pipeline.
- Management raised full-year guidance for all three brands, indicating improved outlooks across key product lines.
- The stock is benefiting from broader sector tailwinds, as healthcare peers like Thermo Fisher and Medtronic also exceeded growth expectations, reinforcing positive sentiment in the health care space.
Sixth Month Growth Performance
When is the next earnings date for TEVA PHARMACEUTICAL INDUSTRIES (TEVA)?
TEVA is scheduled to release its next earnings report on November 3, 2026, before market opens. This upcoming disclosure will cover the company's third-quarter fiscal results for the period ending in late September. Investors should anticipate this update as part of TEVA's consistent quarterly reporting cadence observed throughout the past year.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Teva's stock, with a target price suggesting potential growth ahead.
Financial Health
Teva is producing strong revenue and cash flow, indicating good overall financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Volume & Scale
Teva’s large manufacturing footprint drives cost advantages in generics, which can support margins — though pricing pressure and competition remain important caveats.
Speciality Pipeline Focus
Selective branded assets and R&D in areas like CNS could offer upside if successful, but development outcomes and regulatory hurdles create uncertainty.
Balance Sheet Watch
Investors often focus on debt reduction and cash flow recovery; improvements can strengthen prospects, while unresolved liabilities can limit flexibility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
